CD45-targeted antibody- radioimmunoconjugate conju 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Iomab-B (I-131-apamistamab) / Actinium
SIERRA, NCT02665065: Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Checkmark Top line data from SIERRA trial for r/r AML
Oct 2022 - Oct 2022: Top line data from SIERRA trial for r/r AML
Checkmark Data from SIERRA trial for r/r AML
Apr 2022 - Apr 2022: Data from SIERRA trial for r/r AML
Checkmark Patient enrollment completed in P3 SIERRA trial for AML
More
Active, not recruiting
3
153
Canada, US
Iomab-B, Conventional Care, HCT
Actinium Pharmaceuticals
Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
06/22
12/26
NCI-2018-01788, NCT03670966: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Recruiting
1/2
30
US
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, At 211 MAb BC8-B10, APAMISTAMAB-B10-ASTATINE AT-211, Cyclophosphamide, (-)-Cyclophosphamide, Asta B 518, B-518, WR-138719, Total-Body Irradiation, Total Body Irradiation, SCT_TBI, Whole Body Irradiation, Whole-Body Irradiation, TBI, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, Bone Marrow Transplantation, Bone Marrow Grafting, BMT, Mycophenolate Mofetil, 115007-34-6, MMF, Cellcept, Recombinant Granulocyte Colony-Stimulating Factor, 143011-72-7, Recombinant Colony-Stimulating Factor 3, rhG-CSF, Fludarabine Phosphate, 2-F-ara-AMP, Beneflur, Fludara, Fludarabine-5''-Monophosphate, SH T 586, Tacrolimus, Prograf, Protopic, FK 506, FK-506, Tacforius, Bone Marrow Aspiration and Biopsy, Biospecimen Collection, Biological Sample Collection
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia, Hematopoietic and Lymphoid Cell Neoplasm
06/27
03/29
NCT06768905: Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma

Not yet recruiting
1/2
30
US
Iomab-B, Iomab-ACT, 131I-Apamistamab, CAR-T cell, CAR-T cell therapy
University of Texas Southwestern Medical Center, Actinium Pharmaceuticals
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
05/28
05/29
NCT04083183: Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Suspended
1/2
40
US
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Astatine 211-Labeled Anti-CD45 Monoclonal Antibody BC8-B10, Astatine At 211 MAb BC8-B10, At 211 Anti-CD45 Monoclonal Antibody BC8-B10, At 211 MAb BC8-B10, APAMISTAMAB-B10-ASTATINE AT-211, Fludarabine, 2-Fluorovidarabine, 21679-14-1, 9-Beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine, 9-Beta-D-arabinofuranosyl-2-fluoroadenine, Fluradosa, 2-Fluoro-9-beta-arabinofuranosyladenine, 2-Fluorovidarabine, 21679-14-1, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclostin, Cyclostine, Cytoxan, WR-138719, Lapine T-Lymphocyte Immune Globulin, Anti-thymocyte Globulin Rabbit, Grafalon, Rabbit Anti-Human Thymocyte Globulin (RATG), Rabbit Anti-Thymocyte Globulin, Rabbit Antithymocyte Globulin, Rabbit ATG, rATG, Thymoglobulin, Total-Body Irradiation, TBI, TOTAL BODY IRRADIATION, Whole Body Irradiation, Whole-Body Irradiation, SCT_TBI, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Transplantation, HSCT, Stem Cell Transplant, Mycophenolate Mofetil, Cellcept, MMF, 115007-34-6, Sirolimus, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217, Bone Marrow Aspiration, Biospecimen Collection
Fred Hutchinson Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Non-Malignant Neoplasm
01/28
01/28
MED20-165, NCT04512716: Iomab-ACT: a Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Recruiting
1
6
US
131-I Apamistamab, Iomab-B, CAR T-cell
Memorial Sloan Kettering Cancer Center, Actinium Pharmaceuticals
B-ALL, DLBCL, B ALL, Dlbcl-Ci, DLBCL Unclassifiable, DLBCL, Nos Genetic Subtypes, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type, Diffuse Large B-cell Lymphoma, HGBL, HGBL, Nos
01/26
01/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Iomab-B (I-131-apamistamab) / Actinium
SIERRA, NCT02665065: Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Checkmark Top line data from SIERRA trial for r/r AML
Oct 2022 - Oct 2022: Top line data from SIERRA trial for r/r AML
Checkmark Data from SIERRA trial for r/r AML
Apr 2022 - Apr 2022: Data from SIERRA trial for r/r AML
Checkmark Patient enrollment completed in P3 SIERRA trial for AML
More
Active, not recruiting
3
153
Canada, US
Iomab-B, Conventional Care, HCT
Actinium Pharmaceuticals
Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
06/22
12/26
NCI-2018-01788, NCT03670966: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Recruiting
1/2
30
US
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, At 211 MAb BC8-B10, APAMISTAMAB-B10-ASTATINE AT-211, Cyclophosphamide, (-)-Cyclophosphamide, Asta B 518, B-518, WR-138719, Total-Body Irradiation, Total Body Irradiation, SCT_TBI, Whole Body Irradiation, Whole-Body Irradiation, TBI, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, Bone Marrow Transplantation, Bone Marrow Grafting, BMT, Mycophenolate Mofetil, 115007-34-6, MMF, Cellcept, Recombinant Granulocyte Colony-Stimulating Factor, 143011-72-7, Recombinant Colony-Stimulating Factor 3, rhG-CSF, Fludarabine Phosphate, 2-F-ara-AMP, Beneflur, Fludara, Fludarabine-5''-Monophosphate, SH T 586, Tacrolimus, Prograf, Protopic, FK 506, FK-506, Tacforius, Bone Marrow Aspiration and Biopsy, Biospecimen Collection, Biological Sample Collection
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia, Hematopoietic and Lymphoid Cell Neoplasm
06/27
03/29
NCT06768905: Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma

Not yet recruiting
1/2
30
US
Iomab-B, Iomab-ACT, 131I-Apamistamab, CAR-T cell, CAR-T cell therapy
University of Texas Southwestern Medical Center, Actinium Pharmaceuticals
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
05/28
05/29
NCT04083183: Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Suspended
1/2
40
US
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Astatine 211-Labeled Anti-CD45 Monoclonal Antibody BC8-B10, Astatine At 211 MAb BC8-B10, At 211 Anti-CD45 Monoclonal Antibody BC8-B10, At 211 MAb BC8-B10, APAMISTAMAB-B10-ASTATINE AT-211, Fludarabine, 2-Fluorovidarabine, 21679-14-1, 9-Beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine, 9-Beta-D-arabinofuranosyl-2-fluoroadenine, Fluradosa, 2-Fluoro-9-beta-arabinofuranosyladenine, 2-Fluorovidarabine, 21679-14-1, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclostin, Cyclostine, Cytoxan, WR-138719, Lapine T-Lymphocyte Immune Globulin, Anti-thymocyte Globulin Rabbit, Grafalon, Rabbit Anti-Human Thymocyte Globulin (RATG), Rabbit Anti-Thymocyte Globulin, Rabbit Antithymocyte Globulin, Rabbit ATG, rATG, Thymoglobulin, Total-Body Irradiation, TBI, TOTAL BODY IRRADIATION, Whole Body Irradiation, Whole-Body Irradiation, SCT_TBI, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Transplantation, HSCT, Stem Cell Transplant, Mycophenolate Mofetil, Cellcept, MMF, 115007-34-6, Sirolimus, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217, Bone Marrow Aspiration, Biospecimen Collection
Fred Hutchinson Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Non-Malignant Neoplasm
01/28
01/28
MED20-165, NCT04512716: Iomab-ACT: a Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Recruiting
1
6
US
131-I Apamistamab, Iomab-B, CAR T-cell
Memorial Sloan Kettering Cancer Center, Actinium Pharmaceuticals
B-ALL, DLBCL, B ALL, Dlbcl-Ci, DLBCL Unclassifiable, DLBCL, Nos Genetic Subtypes, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type, Diffuse Large B-cell Lymphoma, HGBL, HGBL, Nos
01/26
01/26

Download Options